Asia Pacific Cell and Gene Therapy Manufacturing Services Market Forecast to 2030 - Regional Analysis - by Type, Indication (Cancer, Orthopedics, and Others), Application (Clinical Manufacturing and Commercial Manufacturing), and End User
아시아태평양의 세포·유전자 치료 제조 서비스 시장은 2022년 10억 742만 달러에서 2030년에는 36억 1,318만 달러로 성장할 것으로 예측되고 있습니다. 2022-2030년의 CAGR은 17.3%로 추정됩니다.
세포 및 유전자 치료 제조 서비스의 자동화는 아시아태평양 세포 및 유전자 치료 제조 서비스 시장을 주도하고 있습니다.
세포 및 유전자 치료제 제조에 자동화를 도입하면 오염 위험을 줄이고 일관성을 높이며 제조 비용을 절감할 수 있으며, Lonza의 Cocoon과 Miltenyi의 CliniMACS Prodigy 시스템은 자동화를 가능하게 하는 시중에서 판매되는 장비 중 일부입니다. 이 제품들은 단일 시스템 내에서 CAR-T 공정의 대부분의 연속적인 단위 작업을 자동화할 수 있도록 설계되었습니다. 세포 및 유전자 치료에 대한 수요가 증가함에 따라 전 세계에서 세포 및 유전자 치료 제품 생산은 소량 생산에서 대량 생산으로 전환되고 있습니다. 2020년 7월, Thermo Fisher Scientific Inc.와 Lyell Immunopharma는 암 환자를 위한 효과적인 세포 치료제를 개발하기 위해 암 환자를 위한 세포치료제 생산에 대한 자동화를 위한 협약을 체결하였습니다. 암 환자를 위한 효과적인 세포 치료제를 설계하는 프로세스 개발 및 제조를 위해 제휴를 맺었습니다. 이 제휴에 따라 양사는 T 세포의 능력을 향상시키기 위해 시약, 소모품, 장비와 함께 cGMP(current good manufacturing practice)를 준수하는 통합 플랫폼(시스템 및 소프트웨어)의 개발을 지원합니다. 이처럼 자동화는 아시아태평양의 세포 및 유전자 치료제 제조 서비스 시장에서 새로운 트렌드로 부상하고 있습니다.
아시아태평양 세포 및 유전자 치료제 제조 서비스 시장 개요
아시아태평양은 중국, 일본, 인도, 호주, 한국 및 기타 아시아태평양으로 구성되어 있습니다. 아시아태평양은 세포 및 유전자 치료 부문의 주요 지역 중 하나이며, 이러한 치료법의 연구 및 개발에 투자하는 여러 국가가 있습니다. 세포 및 유전자 치료와 관련하여 일본은 아시아태평양의 선두주자 중 하나이며, 2014년 일본은 황반변성 치료제인 세포치료제를 승인한 최초의 국가가 되었습니다. 이후에도 백혈병과 림프종에 대한 CAR-T 등 여러 세포-유전자 치료제가 일본에서 승인되었습니다.
중국은 2003년 유전자 치료를 승인한 최초의 국가로, 그 이후 전 세계에서 세포치료와 유전자 치료의 개발이 급속히 발전하고 있으며, 그 치료 잠재력이 급증하고 있습니다. 중국 정부는 세포 및 유전자 치료의 규범적 발전을 촉진하기 위해 여러 가지 규제 개혁을 실시했으며, 2021년Nature 지에 발표된 연구에 따르면 중국은 전 세계 세포 치료 시험의 50% 이상을 수행했습니다. 현재 중국에서는 혈액학, 종양학, 고형암을 중심으로 약 400건의 CAR-T 임상시험이 진행 중입니다. 중국에서는 2021년 Fosun Kite의 Yescarta와 JW Therapeutics의 Relma-cel이 국가약품감독관리국(NMPA)의 승인을 받으면서 세포치료가 새로운 시대를 맞이하고 있습니다. 비용 감소와 환자 수 증가로 인해 여러 다국적 기업이 이러한 요인을 활용하기 위해 이 지역에 진출하고 있습니다.
아시아태평양 세포 및 유전자 치료 제조 서비스 시장 매출 및 2030년까지의 예측(금액)
아시아태평양 세포 및 유전자 치료제 제조 서비스 시장 세분화
아시아태평양 세포 및 유전자 치료 제조 서비스 시장은 유형, 적응증, 용도, 최종사용자 및 국가별로 분류됩니다.
유형별로 아시아태평양 세포 및 유전자 치료 제조 서비스 시장은 세포 치료와 유전자 치료로 구분되며, 2022년 아시아태평양 세포 및 유전자 치료 제조 서비스 시장에서 세포 치료 부문이 더 큰 점유율을 차지할 것으로 예상됩니다. 세포 치료 부문은 자가 유래와 동종 이계로 더 세분화됩니다. 유전자 치료 부문은 다시 바이러스 벡터와 비바이러스 벡터로 구분됩니다.
적응증에 따라 아시아태평양 세포 및 유전자 치료 제조 서비스 시장은 암, 정형외과, 기타로 구분되며, 2022년에는 암 부문이 아시아태평양 세포 및 유전자 치료 제조 서비스 시장에서 가장 큰 점유율을 차지할 것으로 예상됩니다.
용도별로 아시아태평양 세포 및 유전자 치료 제조 서비스 시장은 임상 제조와 상업 제조로 구분되며, 2022년에는 상업 제조 부문이 아시아태평양 세포 및 유전자 치료 제조 서비스 시장에서 가장 큰 점유율을 차지할 것으로 예상됩니다.
최종사용자에 따라 아시아태평양 세포 및 유전자 치료 제조 서비스 시장은 제약 및 생명공학 기업과 계약 연구 기관(CRO)으로 양분되며, 2022년 아시아태평양 세포 및 유전자 치료 제조 서비스 시장에서 제약 및 생명공학 기업 부문은 더 큰 점유율을 기록했습니다.
국가별로는 아시아태평양 세포 및 유전자 치료 제조 서비스 시장은 중국, 일본, 인도, 호주, 한국, 기타 아시아태평양으로 구분되며, 2022년 중국은 아시아태평양 세포 및 유전자 치료 제조 서비스 시장에서 가장 큰 점유율을 기록할 것으로 예상됩니다.
Catalent Inc, Charles River Laboratories International Inc, FUJIFILM Holdings Corp, Lonza Group AG, Merck KgaA, Nikon Corp, Takara Bio Inc, Thermo Fisher Scientific Inc, WuXi AppTec Co Ltd는 아시아태평양의 세포 및 유전자 치료 제조 서비스 시장에서 활동하는 주요 기업입니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 아시아태평양의 세포·유전자 치료 제조 서비스 시장 - 주요 산업 역학
- 주요 시장 촉진요인
- 세포·유전자 치료 승인 건수의 증가
- 세포·유전자 치료 제조 아웃소싱의 인기 상승
- 시장 억제요인
- 시장 기회
- 향후 동향
- 영향 분석
제5장 세포·유전자 치료 제조 서비스 시장 : 아시아태평양 시장 분석
- 아시아태평양의 세포·유전자 치료 제조 서비스 시장 매출, 2022-2030년
제6장 아시아태평양의 세포·유전자 치료 제조 서비스 시장 : 2030년까지의 매출과 예측 : 유형별
- 서론
- 아시아태평양의 세포·유전자 치료 제조 서비스 시장 2022년·2030년 매출 점유율(%) : 유형별
- 세포치료
- 유전자 치료
제7장 아시아태평양의 세포·유전자 치료 제조 서비스 시장 2030년까지의 분석과 예측 : 적응증별
- 서론
- 아시아태평양의 세포·유전자 치료 제조 서비스 시장 : 2022년·2030년(%) : 적응증별
- 암
- 정형외과
- 기타
제8장 아시아태평양의 세포·유전자 치료 제조 서비스 시장 : 매출과 2030년까지의 예측 : 용도별
- 서론
- 아시아태평양의 세포·유전자 치료 제조 서비스 시장 2022년·2030년 매출 점유율(%) : 용도별
- 임상 제조
- 상업용 제조
제9장 아시아태평양의 세포·유전자 치료 제조 서비스 시장 : 2030년까지의 매출과 예측 : 최종사용자별
- 서론
- 아시아태평양 세포·유전자 치료 제조 서비스 시장 매출 점유율 2022년·2030년(%) : 최종사용자별
- 제약기업과 바이오테크놀러지 기업
- CRO(임상시험수탁기관)
제10장 아시아태평양의 세포·유전자 치료 제조 서비스 시장 : 2030년까지의 매출과 예측 : 국가별 분석
제11장 아시아태평양의 세포·유전자 치료 제조 서비스 시장 : 업계 상황
- 서론
- 아시아태평양의 세포·유전자 치료 제조 서비스 시장에서의 성장 전략
- 유기적 성장 전략
- 무기적 성장 전략
제12장 기업 개요
- Thermo Fisher Scientific Inc
- Merck KGaA
- Charles River Laboratories International Inc
- Lonza Group AG
- WuXi AppTec Co Ltd
- Catalent Inc
- Takara Bio Inc
- Nikon Corp
- FUJIFILM Holdings Corp
KSA
The Asia Pacific cell and gene therapy manufacturing services market is expected to grow from US$ 1,007.42 million in 2022 to US$ 3,613.18 million by 2030. It is estimated to grow at a CAGR of 17.3% from 2022 to 2030.
Automation of Cell and Gene Therapy Manufacturing Services Drives Asia Pacific Cell and Gene Therapy Manufacturing Services Market
Incorporating automation in cell and gene therapy manufacturing would lead to a reduced risk of contamination, improved consistency, and decreased cost of production. Lonza Cocoon and the CliniMACS Prodigy system from Miltenyi are a few of the devices available in the market to enable automation. These products have been designed to enable the automation of most sequential unit operations for a CAR-T process within a single system. The rising demand for cell and gene therapies has shifted the production of cell and gene therapy products from a small-volume process to a large-volume process worldwide. In addition to the increasing research activities, the evolution of cell and gene therapy from an academic and clinical setting to mass production and commercialization has propelled the demand for automation in commercial manufacturing. In July 2020, Thermo Fisher Scientific Inc. and Lyell Immunopharma partnered to develop and manufacture processes to design effective cell therapies for cancer patients. Under this partnership, the companies aim to improve the capability of T-cells and support the development of an integrated current good manufacturing practice (cGMP) compliant platform (system and software), along with reagents, consumables, and instruments. Thus, automation is emerging as a new trend in the Asia Pacific cell and gene therapy manufacturing services market.
Asia Pacific Cell and Gene Therapy Manufacturing Services Market Overview
Asia Pacific region comprises of China, Japan, India, Australia, South Korea, and Rest of Asia Pacific countries. The Asia Pacific region is one of the leading regions in the field of cell and gene therapy, with several countries which are involved in the investing in research and development of these therapies. Japan is one of the leaders in the Asia Pacific region when it comes to cell and gene therapies. In 2014, Japan was the first country to approve a cell therapy product, a treatment for macular degeneration. Several other cell and gene therapies have been approved in the country since then, including the CAR-T for leukemia and lymphoma.
China is the first country to approve a gene therapy in 2003, since then cell and gene therapy development has advanced rapidly worldwide, and their therapeutic potential has soared. China's government has conducted several regulatory reforms to promote normative development of cell and gene therapies. According to a study published in Nature in 2021, China is home to more than 50% of all cell therapy trials across the world. Currently, China has nearly 400 ongoing CAR-T trials centered on hematology and oncology and solid tumors. Cell therapy in China is entering a new era with the approval of Fosun Kite's Yescarta and JW Therapeutics' Relma-cel in 2021 from the National Medical Products Administration (NMPA). Due to lower costs and larger patient populations, several multinational companies have moved to the region to take advantage of these factors.
Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Cell and Gene Therapy Manufacturing Services Market Segmentation
The Asia Pacific cell and gene therapy manufacturing services market is segmented into type, indication, application, end user, and country.
Based on type, the Asia Pacific cell and gene therapy manufacturing services market is bifurcated into cell therapy and gene therapy. In 2022, the cell therapy segment registered a larger share in the Asia Pacific cell and gene therapy manufacturing services market. The cell therapy segment is further segmented into autologous and allogenic. The gene therapy segment is further segmented into viral and non-viral vector.
Based on indication, the Asia Pacific cell and gene therapy manufacturing services market is segmented into cancer, orthopedics, and others. In 2022, the cancer segment registered the largest share in the Asia Pacific cell and gene therapy manufacturing services market.
Based on application, the Asia Pacific cell and gene therapy manufacturing services market is segmented into clinical manufacturing and commercial manufacturing. In 2022, the commercial manufacturing segment registered the largest share in the Asia Pacific cell and gene therapy manufacturing services market.
Based on end user, the Asia Pacific cell and gene therapy manufacturing services market is bifurcated into pharmaceutical and biotechnology companies and contract research organization (CROs). In 2022, the pharmaceutical and biotechnology companies segment registered a larger share in the Asia Pacific cell and gene therapy manufacturing services market.
Based on country, the Asia Pacific cell and gene therapy manufacturing services market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. In 2022, China registered the largest share in the Asia Pacific cell and gene therapy manufacturing services market.
Catalent Inc, Charles River Laboratories International Inc, FUJIFILM Holdings Corp, Lonza Group AG, Merck KgaA, Nikon Corp, Takara Bio Inc, Thermo Fisher Scientific Inc, and WuXi AppTec Co Ltd are some of the leading companies operating in the Asia Pacific cell and gene therapy manufacturing services market.
Table Of Contents
1. Introduction
- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation
2. Executive Summary
3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
4. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Key Industry Dynamics
- 4.1 Key Market Drivers:
- 4.1.1 Increase in Number of Approval of Cell and Gene Therapies
- 4.1.2 Increasing Popularity of Outsourcing Cell and Gene Therapy Manufacturing
- 4.2 Market Restraints
- 4.2.1 High Cost of Cell and Gene Therapy Manufacturing
- 4.3 Market Opportunities
- 4.3.1 Strategic Initiatives by Companies
- 4.4 Future Trends
- 4.4.1 Automation of Cell and Gene Therapy Manufacturing Services
- 4.5 Impact Analysis:
5. Cell and Gene Therapy Manufacturing Services Market - Asia Pacific Market Analysis
- 5.1 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue (US$ Mn), 2022 - 2030
6. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by Type
- 6.1 Overview
- 6.2 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
- 6.3 Cell Therapy
- 6.3.1 Overview
- 6.3.2 Cell Therapy: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
- 6.3.2.1 Autologous
- 6.3.2.1.1 Overview
- 6.3.2.1.2 Autologous: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
- 6.3.2.2 Allogenic
- 6.3.2.2.1 Overview
- 6.3.2.2.2 Allogenic: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
- 6.4 Gene Therapy
- 6.4.1 Overview
- 6.4.2 Gene Therapy: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
- 6.4.2.1 Viral Vector
- 6.4.2.1.1 Overview
- 6.4.2.1.2 Viral Vector: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
- 6.4.2.2 Non-Viral Vector
- 6.4.2.2.1 Overview
- 6.4.2.2.2 Non-Viral Vector: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
7. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Analysis and Forecasts to 2030 - by Indication
- 7.1 Overview
- 7.2 Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
- 7.3 Cancer
- 7.3.1 Overview
- 7.3.2 Cancer: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
- 7.4 Orthopedics
- 7.4.1 Overview
- 7.4.2 Orthopedics: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
- 7.5 Others
- 7.5.1 Overview
- 7.5.2 Others: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by Application
- 8.1 Overview
- 8.2 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
- 8.4 Clinical Manufacturing
- 8.4.1 Overview
- 8.4.2 Clinical Manufacturing: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
- 8.5 Commercial Manufacturing
- 8.5.1 Overview
- 8.5.2 Commercial Manufacturing: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by End User
- 9.1 Overview
- 9.2 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
- 9.4 Pharmaceutical and Biotechnology Companies
- 9.4.1 Overview
- 9.4.2 Pharmaceutical & Biotechnology Companies: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
- 9.5 Contract Research Organizations (CROs)
- 9.5.1 Overview
- 9.5.2 Contract Research Organizations (CROs): Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
10. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - Country Analysis
- 10.1 Overview
- 10.1.1 Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
- 10.1.1.1 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.1.1 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
- 10.1.1.1.1.1 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
- 10.1.1.1.1.2 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
- 10.1.1.1.2 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
- 10.1.1.1.3 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
- 10.1.1.1.4 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
- 10.1.1.2 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.2.1 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
- 10.1.1.2.1.1 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
- 10.1.1.2.1.2 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
- 10.1.1.2.2 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
- 10.1.1.2.3 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
- 10.1.1.2.4 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
- 10.1.1.3 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.3.1 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
- 10.1.1.3.1.1 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
- 10.1.1.3.1.2 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
- 10.1.1.3.2 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
- 10.1.1.3.3 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
- 10.1.1.3.4 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
- 10.1.1.4 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.4.1 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
- 10.1.1.4.1.1 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
- 10.1.1.4.1.2 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
- 10.1.1.4.2 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
- 10.1.1.4.3 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
- 10.1.1.4.4 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
- 10.1.1.5 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.5.1 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
- 10.1.1.5.1.1 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
- 10.1.1.5.1.2 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
- 10.1.1.5.2 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
- 10.1.1.5.3 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
- 10.1.1.5.4 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
- 10.1.1.6 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.6.1 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
- 10.1.1.6.1.1 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
- 10.1.1.6.1.2 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
- 10.1.1.6.2 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
- 10.1.1.6.3 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
- 10.1.1.6.4 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
11. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Industry Landscape
- 11.1 Overview
- 11.2 Growth Strategies in Asia Pacific Cell and Gene Therapy Manufacturing Services Market
- 11.3 Organic Growth Strategies
- 11.4 Inorganic Growth Strategies
12. Company Profiles
- 12.1 Thermo Fisher Scientific Inc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
- 12.2 Merck KGaA
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
- 12.3 Charles River Laboratories International Inc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
- 12.4 Lonza Group AG
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
- 12.5 WuXi AppTec Co Ltd?
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
- 12.6 Catalent Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
- 12.7 Takara Bio Inc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
- 12.8 Nikon Corp
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
- 12.9 FUJIFILM Holdings Corp
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
